Literature DB >> 27057459

Neuroblastoma arginine addiction subverts the anticancer immune response.

Carmela De Santo1, Francis Mussai1.   

Abstract

High-risk neuroblastoma continues to have a poor prognosis, stimulating the ongoing development of alternative immune-therapy approaches. Despite exciting preclinical results, clinical outcomes have been less clear. Recently we identified that neuroblastoma expresses Arginase II, depleting local and systemic arginine concentrations, and suppression of autologous and engineered T cell immunity.

Entities:  

Year:  2015        PMID： 27057459      PMCID： PMC4801431          DOI： 10.1080/2162402X.2015.1078967

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

2.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Authors:  Chrystal U Louis; Barbara Savoldo; Gianpietro Dotti; Martin Pule; Eric Yvon; G Doug Myers; Claudia Rossig; Heidi V Russell; Oumar Diouf; Enli Liu; Hao Liu; Meng-Fen Wu; Adrian P Gee; Zhuyong Mei; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Blood       Date:  2011-10-07       Impact factor: 22.113

Review 3.  Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities.

Authors:  Francis Mussai; Carmela De Santo; Vincenzo Cerundolo
Journal:  J Immunother       Date:  2012-07       Impact factor: 4.456

Review 4.  Small-molecule arginase inhibitors.

Authors:  Yan A Ivanenkov; Nina V Chufarova
Journal:  Pharm Pat Anal       Date:  2014-01

5.  L-arginine availability regulates T-lymphocyte cell-cycle progression.

Authors:  Paulo C Rodriguez; David G Quiceno; Augusto C Ochoa
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

6.  A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.

Authors:  Deepa K Krishnadas; Suzanne Shusterman; Fanqi Bai; Lisa Diller; Janice E Sullivan; Alexandra C Cheerva; Rani E George; Kenneth G Lucas
Journal:  Cancer Immunol Immunother       Date:  2015-06-24       Impact factor: 6.968

7.  L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes.

Authors:  Arnold H Zea; Paulo C Rodriguez; Kirk S Culotta; Claudia P Hernandez; Joanna DeSalvo; Juan B Ochoa; Hae-Joon Park; Jovanny Zabaleta; Augusto C Ochoa
Journal:  Cell Immunol       Date:  2005-02-23       Impact factor: 4.868

8.  Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.

Authors:  Francis Mussai; Carmela De Santo; Issa Abu-Dayyeh; Sarah Booth; Lynn Quek; Rosanna M McEwen-Smith; Amrana Qureshi; Francesco Dazzi; Paresh Vyas; Vincenzo Cerundolo
Journal:  Blood       Date:  2013-06-03       Impact factor: 22.113

9.  Immunosuppressive microenvironment in neuroblastoma.

Authors:  Vito Pistoia; Fabio Morandi; Giovanna Bianchi; Annalisa Pezzolo; Ignazia Prigione; Lizzia Raffaghello
Journal:  Front Oncol       Date:  2013-06-26       Impact factor: 6.244

10.  Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

Authors:  Francis Mussai; Sharon Egan; Stuart Hunter; Hannah Webber; Jonathan Fisher; Rachel Wheat; Carmel McConville; Yordan Sbirkov; Kate Wheeler; Gavin Bendle; Kevin Petrie; John Anderson; Louis Chesler; Carmela De Santo
Journal:  Cancer Res       Date:  2015-06-08       Impact factor: 12.701
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.